EU countries to resume AstraZeneca COVID-19 vaccines

AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

The European Union (EU) countries said they would resume AstraZeneca coronavirus vaccinations after the EuropeanMedicine Agency (EMA) said the jab is “safe and effective” and not associated with a blood clot risk.

This came after the World Health Organisation (WTO) said the vaccine was safe.

Among the countries scheduled to resume the vaccine including Germany, France, Spain, Italy, the Netherlands, Portugal, Lithuania, Latvia, Slovenia and Bulgaria.

The EMA’s chief Emer Cooke said Thursday that after an investigation into the AstraZeneca jab, its “committee has come to a clear scientific conclusion: this is a safe and effective vaccine”.

“The committee also concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots,” she added.

AstraZeneca’s chief medical officer Ann Taylor said that “vaccine safety is paramount and we welcome the regulators’ decisions which affirm the overwhelming benefit of our vaccine in stopping the pandemic”.

However, Norway and Sweden said they were not ready to resume using the vaccine.

FOLLOW US ON:
Moderna rolls out va
AstraZeneca COVID-19
Rate This Article: